admin

Despite decades of efforts to develop a drug that prevents­­ or cures Alzheimer’s disease (AD), the most prevalent form of dementia afflicting our aging population, there is currently no treatment for this devastating condition. Emerging research suggests that such a miracle treatment might already exist, not in the form of a pill, but as a […]

by

Editorial: Steve McIver, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: http://www.ptcommunity.com/headlines

by

The Drug Enforcement Administration’s decision last week not to reschedule marijuana highlights the absurdities of its pre-election limbo. Marijuana will remain a Schedule I drug, meaning that the federal government doesn’t recognize any of its medical uses and considers it to have high potential for abuse. “This decision isn’t based on danger,” DEA chief Chuck […]

by

PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of […]

by

Piper Jaffray analyst Joshua Schimmer provides a 2H16 outlook on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH). Exiting second-quarter earnings season, GWPH remains one of Schimmer’s top mid-cap picks. In light of positive expectations after finding 2016 a “noteworthy success for the company,” Schimmer reiterates an Overweight rating with a $147 price target, which represents a nearly […]

by

Piper Jaffray analyst Joshua Schimmer provides a 2H16 outlook on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH). Exiting second-quarter earnings season, GWPH remains one of Schimmer’s top mid-cap picks. In light of positive expectations after finding 2016 a “noteworthy success for the company,” Schimmer reiterates an Overweight rating with a $147 price target, which represents a nearly […]

by

Disclaimer: Epilepsy Research UK is completely neutral and is not affiliated with any commercial company, or any particular device/product. The medical company, MMJ PhytoTech Limited, has recently announced that it will begin a new phase two clinical trial by the end of this year to test the effectiveness of its new drug compound, PTL101, in treating children with […]

by

LOS ANGELES–(BUSINESS WIRE)– Phytecs is expanding its preclinical research program on its novel fluorinated cannabidiol, HUF-101, along with its family of related drug molecules developed by noted medicinal chemist and Phytecs Director of Global Research, Prof. Raphael Mechoulam of The Hebrew University of Jerusalem. A new preclinical study found HUF-101 effective in mice models predictive […]

by

Disclaimer: Epilepsy Research UK is completely neutral and is not affiliated with any commercial company, or any particular device/product. The medical company, MMJ PhytoTech Limited, has recently announced that it will begin a new phase two clinical trial by the end of this year to test the effectiveness of its new drug compound, PTL101, in treating children with […]

by

Smoking pot will soon be as retro as smoking a cigar or enjoying a fine wine. As the legal market for marijuana expands, product offerings have diversified from the standard dried flowers and cannabis-infused edible items like cookies and gummy bears to vaporizable oils and concentrates. They have become a major portion of legal marijuana […]

by

MMJ PhytoTech Limited (ASX:MMJ) (“MMJ” or “the Company”) is pleased to advise that its wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Limited (“PTL”), will commence a Phase 2 clinical study into the efficacy of the its PTL101 capsules in treating intractable epilepsy in children. Highlights: – Phase 2 clinical trial of PTL101 capsules to commence Q4 2016 […]

by